A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

Blood

Volumn 127, Issue 4, 2016, Pages 411-419

  Walter, Harriet S ^a   Rule, Simon A ^b   Dyer, Martin J S ^a   Karlin, Lionel ^c   Jones, Ceri ^d   Cazin, Bruno ^e   Quittet, Philippe ^f   Shah, Nimish ^b   Hutchinson, Claire V ^a,b   Honda, Hideyuki ^g   Duffy, Kevin ^g   Birkett, Joseph ^g   Jamieson, Virginia ^g   Courtenay Luck, Nigel ^g   Yoshizawa, Toshio ^g   Sharpe, John ^g   Ohno, Tomoya ^g   Abe, Shinichiro ^g   Nishimura, Akihisa ^g   Cartron, Guillaume ^f   Morschhauser, Franck ^f   Fegan, Christopher ^d   Salles, Gilles ^c   more..

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b PLYMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITÉ LYON 1   (France)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f CNRS   (France)

^g ONO PHARMACEUTICAL CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRUTON TYROSINE KINASE INHIBITOR; ONO GS 4059; UNCLASSIFIED DRUG; AGAMMAGLOBULINAEMIA TYROSINE KINASE; GS-4059; IMIDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; B CELL LYMPHOMA; BLEEDING; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED ANEMIA; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; HEART FAILURE; HEART INFARCTION; HEMATOMA; HUMAN; ILIOPSOAS HEMATOMA; LARGE CELL LYMPHOMA; LOW DRUG DOSE; LOWER RESPIRATORY TRACT INFECTION; LYMPH NODE; LYMPHOCYTOSIS; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PETECHIA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PURPURA; RHINOPHARYNGITIS; SKIN BRUISING; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; URTICARIA; ANTAGONISTS AND INHIBITORS; B LYMPHOCYTE; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, MANTLE-CELL; MIDDLE AGED; PATHOLOGY; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; B-LYMPHOCYTES; COHORT STUDIES; FEMALE; HUMANS; IMIDAZOLES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 84958230944     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-08-664086     Document Type: Article

References (30)

1. Mohamed AJ, Yu L, Bäckesjö CM, et al. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev. 2009;228(1):58-73.
2. de Weers M, Verschuren MC, Kraakman ME, et al. The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages. Eur J Immunol. 1993;23(12):3109-3114.
3. Hyvö nen M, Saraste M. Structure of the PH domain and Btk motif from Bruton's tyrosine kinase: molecular explanations for X-linked agammaglobulinaemia. EMBO J. 1997;16(12):3396-3404.
4. Saito K, Scharenberg AM, Kinet JP. Interaction between the Btk PH domain and phosphatidylinositol-3, 4, 5-trisphosphate directly regulates Btk. J Biol Chem. 2001;276(19):16201-16206.
5. Hendriks RW, Bredius RG, Pike-Overzet K, Staal FJ. Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man. Expert Opin Ther Targets. 2011;15(8):1003-1021.
6. Hutchinson CV, Dyer MJ. Breaking good: the inexorable rise of BTK inhibitors in the treatment of chronic lymphocytic leukaemia. Br J Haematol. 2014;166(1):12-22.
7. Pan Z, Scheerens H, Li SJ, et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. Chem Med Chem. 2007;2(1):58-61.
8. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
9. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-516.
10. Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015;372(15):1430-1440.
11. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107(29):13075-13080.
12. Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539-2549.
13. Grabinski N, Ewald F. Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells. Invest New Drugs. 2014;32(6):1096-1104.
14. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88-94.
15. McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124(25):3829-3830.
16. Smith MR. Ibrutinib in B lymphoid malignancies. Expert Opin Pharmacother. 2015;16(12):1879-1887.
17. Tucker DL, Rule SA. A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. Ther Clin Risk Manag. 2015;11:979-990.
18. Gao W, Wang M, Wang L, et al. Selective antitumor activity of ibrutinib in EGFR-mutant nonsmall cell lung cancer cells. J Natl Cancer Inst. 2014;106(9).
19. Harandi A, Zaidi AS, Stocker AM, Laber DA. Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J Oncol. 2009;2009:567486.
20. Di Paolo JA, Huang T, Balazs M, et al. Specific Btk inhibition suppresses B cell- and myeloid cellmediated arthritis. Nat Chem Biol. 2011;7(1):41-50.
21. Yasuhiro T, Yoshizawa T, Daub H, Weber C, Narita M, Kawabata K. ONO-WG-307, a novel, potent and selective inhibitor of Bruton's tyrosine kinase (Btk), results in sustained inhibition of the ERK, AKT and PKD signaling pathways. Cancer Res. 2012;72 (suppl 8). Abstract 2021.
22. Kozaki R, Hutchinson C, Sandrine J, Dyer M J S. Kinome reprogramming in DLBCL by the BTK-specific inhibitor ONO-4059 highlights synergistic combinations for clinical application [abstract]. Haematologica. 2014;99(S1):137-138. Abstract P431.
23. Kozaki R, Yoshizawa T, Tohda S, et al. Development of a bruton's tyrosine kinase (btk) inhibitor, ONO-WG-307: efficacy in ABC-DLBCL xenograft model potential treatment for B-cell malignancies [abstract]. Blood. 2011;118(21). Abstract 3731.
24. Hallek M, Cheson BD, Catovsky D, et al; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
25. Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123(12):1810-1817.
26. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282.
27. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.
28. Owen RG, Kyle RA, Stone MJ, et al; VIth International Workshop on Waldenströ m macroglobulinaemia. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013;160(2):171-176.
29. Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922-926.
30. Wang Y, Zhang LL, Champlin RE, Wang ML. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies. Clin Pharmacol Ther. 2015;97(5):455-468.